2021 13th NYKB Conference

NYKB ๊ฐ€์กฑ ์—ฌ๋Ÿฌ๋ถ„ ์•ˆ๋…•ํ•˜์„ธ์š”!

์ œ 13ํšŒ NYKBํ•™์ˆ ๋Œ€ํšŒ๊ฐ€ ์˜ค๋Š” 4์›” 16์ผ๊ณผ 4์›” 17์ผ ์–‘์ผ์— ๊ฑธ์ณ ์˜จ๋ผ์ธ ํฌ๋งท์œผ๋กœ ๊ฐœ์ตœ๋ฉ๋‹ˆ๋‹ค. AI์™€ Microbiome ์—ฐ๊ตฌ๋ฅผ ์„ ๋„ํ•˜๋Š” ๋‘ ๋ถ„์˜ ํ‚ค๋…ธํŠธ ์—ฐ์‚ฌ๋ถ„๊ณผ ๊ตญ๋‚ด๊ธฐ์—…์˜ ์‹ค๋ฌด์ž๋ถ„๋“ค, ๊ทธ๋ฆฌ๊ณ  ์—ฌ๋Ÿฌ๋ถ„๋ณด๋‹ค ๋จผ์ € ๋‹ค์Œ ์ปค๋ฆฌ์–ด์— ์•ˆ์ฐฉํ•˜์‹  ํŒจ๋„๋ถ„๋“ค๊ณผ ํŽธํ•˜๊ฒŒ ์†Œํ†ตํ•  ์ˆ˜ ์žˆ๋Š” ์‹œ๊ฐ„์„ ๋งˆ๋ จํ•˜์˜€์œผ๋‹ˆ, ํ™œ๋ฐœํ•˜๊ฒŒ ๋„คํŠธ์›Œํ‚น ํ•˜์‹œ๊ธธ ๋ฐ”๋ž๋‹ˆ๋‹ค.ย 

์ด๋ฒˆ ํ•™ํšŒ์˜ ์›ํ™œํ•œ ์ง„ํ–‰์„ ์œ„ํ•ด ์ฐธ์—ฌ๋ฅผ ์›ํ•˜์‹œ๋Š” ๋ถ„๋“ค์€ ์•„๋ž˜ ๋งํฌ์—์„œ ์‚ฌ์ „๋“ฑ๋ก์„ ๋ถ€ํƒ๋“œ๋ฆฝ๋‹ˆ๋‹ค. ๊ฐ์‚ฌํ•ฉ๋‹ˆ๋‹ค.ย 

์ œ 12๋Œ€ ๋‰ด์š•ํ•œ์ธ์ƒ๋ช…๊ณผํ•™์žํ˜‘ํšŒ ํšŒ์žฅ ๋ฐฑ์ •์€ ๋ฐ ํšŒ์žฅ๋‹จ ์˜ฌ๋ฆผ

Keynote Speakers

Keynote Speaker I. ๊น€์„  ๊ต์ˆ˜๋‹˜ (Seoul National University)

Sun Kim is Professor in the School of Computer Science and Engineering, Director of Bioinformatics Institute, and an affiliated faculty for the Interdisciplinary Program in Bioinformatics at Seoul National University. The main research interest in Sun Kimโ€™s lab is to develop computational methods and information systems for characterizing biological mechanisms underlying phenotypes. His computational methods are to relate chemical/molecular features to biological mechanisms, and then to phenotypes such as cancer subtypes, drug response, and toxicity. In other words, Sum Kimโ€™s lab aim to define phenotypes in terms of the molecular and chemical features by identifying important biological functions.

Before joining SNU, he was Chair of Faculty Division C; Director of Center for Bioinformatics Research, an Associate Professor in School of Informatics and Computing at Indiana University (IU) Bloomington. Prior to joining IU in 2001, he worked at DuPont Central Research from 1998 to 2001, and at the University of Illinois at Urbana-Champaign from 1997 to 1998. Sun Kim received B.S and M.S and Ph.D in Computer Science from Seoul National University, KAIST and the University of Iowa, respectively.

Sun Kim is a recipient of Outstanding Junior Faculty Award at Indiana University 2004, US NSF CAREER Award DBI-0237901 in 2003. He is actively contributing to the bioinformatics community, serving on the editorial board for journals including editors for the METHODS journal and, associate editor-in-chief for ACM/IEEE Transactions on Computational Biology and Bioinformatics, having served on the board of directors for ACM SIG Bioinformatics and for education for the IEEE Computer Society Technical Committee on Bioinformatics. Among many service activates in Korea, he served on Samsung Future Technology Committee for 2016-2018, a member of The National Science and Technology Council (NSTC) of the Korean Government for 2019-2020, President of Korea Artificial Intelligence Society (2016-2018) and Vice President of Korea Society of Bioinformatics and Systems Biology (2011-present).

Keynote Speaker II. ์˜ค์„ฑํ™˜ ๊ต์ˆ˜๋‹˜ (Harvard University)

Sungwhan Oh received his bachelorโ€™s degree in chemistry, summa cum laude, at Seoul National University in South Korea in 2003. He moved to Boston for his graduate studies in the Division of Medical Science at Harvard Medical School, and defended his PhD dissertation on the biosynthesis and pro-resolving activity of endogenous lipid mediators in 2009. He continued his postdoctoral training on the gut microbiota and its immunomodulatory factors in the Department of Microbiology and Immunobiology, with support from NIAID NRSA T32 (2011-2013), Crohnโ€™s and Colitis Foundation Research Fellowship Award (2013โ€“2016) and NIDDK Research Scientist Development Award (2015โ€“2020).

Sungwhan joined the Center for Experimental Therapeutics and Reperfusion Injury (CETRI) in the Department of Anesthesiology, Perioperative and Pain Medicine at Brigham and Womenโ€™s Hospital as a faculty member in 2018. Oh lab is a team of young, enthusiastic scientists applying a broad range of knowledge to the dissection of hostโ€“microbiotaโ€“environment interactions. Our combined expertise in chemistry, microbiology, and immunology synergizes our investigations into the structures of molecular factors produced by symbionts and the functions of these factors in host physiology and disease.

Career Development Mentoring Session

์ฐฝ์—… ํŒจ๋„ ์ •๋ณด
  1. Chee-Yeun Chung, Ph.D. (Yumanity Therapeutics)

Dr. Chee Yeun Chung is Director of Discovery Biology and a scientific co-founder at Yumanity who made seminal contributions to both the companyโ€™s neuronal and yeast discovery platforms. Dr. Chung is a graduate of Ewha Womanโ€™s University in Seoul, South Korea, where she earned a bachelor of pharmacy degree. She then obtained her Ph.D. at the University of California, Davis. Prior to joining Yumanity, she was an instructor at Harvard Medical School, subsequently joining the Lindquist lab at the Whitehead Institute as a senior research scientist in 2009. She developed assays that have identified abnormalities in rat and human iPSc-based cortical neuron culture system, revealing critical mechanisms of neurodegenerative diseases. Yumanity is now a clinical stage and publicly traded company with its lead molecule YTX-7739 in clinical trial for Parkinsonโ€™s disease. She showcased Yumanity as a Hive Innovator at TEDMED 2017.

 

  1. Kunwoo Lee, Ph.D. (Genedit)

Dr. Kunwoo Lee is the Co-Founder and CEO of GenEdit. He received a PhD from UC Berkeley in the Department of Bioengineering. He has always had a passion for technology innovation changing peopleโ€™s lives and it led him to involve in CRISPR revolution. He is the inventor of several delivery technologies for CRISPR/Cas9, which have shown great potential to revolutionize the treatment of genetic disorders. He was named as a Forbes 30 under 30 in 2017 and was a Siebel Scholar in 2016.

 

  1. Sungwon Lim, Ph.D. (ImpriMed)

Sungwon Lim is the CEO and Co-Founder of ImpriMed, Inc. He founded ImpriMed with a strong motivation to innovate a way to help cancer patients who need an effective treatment โ€˜today’, by optimizing and personalizing drug treatment options that are currently available in our medical cabinet. His company is building a comparative oncology platform to develop and prove new cell-based, functional precision medicine technologies in the veterinary oncology space first, at a significantly higher speed with by far more comprehensive data than the human oncology space, and then translate the collected database into human cancer care. Dr. Lim received his Ph.D. degree in Bioengineering from Stanford University, and M.S. and B.S. degrees in Chemical and Biomolecular Engineering from KAIST.

๊ตญ๋‚ด๊ต์ˆ˜์ž„์šฉ ํŒจ๋„ ์ •๋ณด
  1. Junghyun Lim, Ph.D. (Jeonbuk National University)

Junghyun Lim is an assistant professor at Jeonbuk National University. His research focuses on mechanisms by which B cells generate high specific antibodies to the innumerable antigens we encounter, but in that process undergo genomic rearrangements and mutations that cause various types of B cell cancers. Another his focus is to understand the role of ncRNA processing by the RNA exosome complex (a 3โ€™-5โ€™ exonuclease) in controlling enhancer/super-enhancer function. Junghyun Lim received his B.S., M.S. and Ph.D. degrees in Genetic Engineering from Kyung Hee University.ย ย 

 

  1. KyeongJin Kim, Ph.D. (Inha University)

KyeongJin Kim, Ph.D, is an assistant professor at College of Medicine, Inha University, South Korea. Her research interests are centered in the discovery of novel, pharmacologically tractable targets in the development and potential treatment of insulin resistance/Type 2 Diabetes (T2D), nonalcoholic fatty liver/steatohepatitis (NAFLD/NASH), dyslipidemia and impairment of energy homeostasis. Her work further intersects fields of metabolism and cancer biology. She received her B.S., M.S. and Ph.D. in Molecular Biology from Pusan National University and was trained in the lab of Prof. Utpal B. Pajvani at Columbia University as a postdoctoral research scientist/associate research scientist.

ย 

  1. Jae-Hoon Choi, Ph.D. (Hanyang University)

Dr. Jae-Hoon Choi is a professor in the department of life science at Hanyang University. He worked as post-doctoral associate in the late Ralph Steinman’s lab at Rockefeller University from 2006~2011. His research interest lies broadly in characterization of immune and non-immune cells in cardiovascular system and their phenotype changes during hyperlipidemic condition to define molecular or cellular therapeutic targets for inflammatory cardiovascular diseases including atherosclerosis and valvular disease. Dr. Choi received his B.S., DVM., and Ph.D. degrees in the college of veterinary medicine at Seoul National University.ย ย 

๋ฏธ๊ตญ๊ต์ˆ˜์ž„์šฉ ํŒจ๋„ ์ •๋ณด
  1. Hee Won Yang, Ph.D. (Columbia)

Hee Won Yang is an assistant professor in the department of Pathology and Cell Biology at Columbia University. The Yang lab is interested in understanding cell cycle regulation both in normal and pathological conditions such as cancer. Analogous to other single-cell technologies, such as single-cell RNA sequencing, they developed and utilized live-cell sensors and single-cell microscopy technologies. This allows them to classify heterogeneity in cell proliferation by monitoring key signaling with higher temporal resolution in a high-throughput manner. Hee Won received his B.S. in Life and Food Science from Handong University and his Ph.D. in Life Science from KAIST.ย 

ย 

  1. Sangmoo Jeong, Ph.D. (Johns hopkins)

Sangmoo Jeong is an Assistant Professor in the Department of Chemical & Biomolecular Engineering at Johns Hopkins University and a core member in the Institute for NanoBioTechnology (INBT). His lab is interested in how metabolic dysfunctions link to major diseases, including cancer. With expertise in device engineering, his lab focuses on developing technologies to deepen our understanding of local and systemic metabolic malfunctions in diseases and identify how our daily diet affects disease progression. Dr. Jeong received his B.S. degree in Electrical Engineering from KAIST and his M.S. and Ph.D. degree in Electrical Engineering from Stanford University. He completed his postdoctoral research at Massachusetts General Hospital/Harvard Medical School and later, Memorial Sloan Kettering Cancer Center. He is a recipient of the NIH Pathway to Independence Award (K99/R00).

ย 

  1. Hwan Keun Kim Ph.D. (Stony)

Dr. Hwan Keun Kim is an Assistant Professor of Microbiology and Immunology at Stony Brook University. His laboratory studies the biology of diverse bacterial and viral pathogens transmitted by ticks and host-pathogen-vector interactions by utilizingย in vitroย tissue culture infections, molecular genetics, biochemical analysis, microscopic characterization, andย in vivoย tick and animal infection models in the high-containment facility.

๊ตญ๋‚ด๊ธฐ์—…์ทจ์—… ํŒจ๋„ ์ •๋ณด
  1. Woosook Kim, Ph.D. (LG Chem)

Woosook Kim currently works as a professional researcher at LG Chem. Her Ph.D. studies at Baylor College of Medicine focused on the tumor microenvironment, in particular identifying origins of myofibroblasts and underlying mechanisms for mesenchymal stem cell activation, proliferation, and differentiation into myofibroblasts. As a postdoctoral researcher at Columbia University, her major focuses were the nature of the association between inflammation and gastrointestinal carcinogenesis and gastrointestinal stem cell biology. She studied the role of the immune system, in particular immune checkpoints, in gastrointestinal cancers and intestinal stem cell/progenitor cell populations under radiation injury.

ย 

  1. Sung Kyun Lee, Ph.D. (Korea Research Institute of Chemical Technology)

Sung Kyun Lee is working in field of diagnosis of infectious diseases at Korea Research Institute of Chemical Technology (KRICT). Dr. Lee was a postdoctoral fellow in the lab of Prof. Paul S. Frenette at Albert Einstein College of medicine. During his postdoctoral fellow years, Dr. Lee mainly focused on changing cellular phenotype, such as aging process of neutrophils.ย In sickle cell disease (SCD), number of aged neutrophils is known to be positively correlated with vaso-occlusive episodes (VOE), which is most common clinical manifestations of the disease. Dr. Lee characterized and determined the transitional process of naรฏve neutrophils toย aged neutrophils which is regulated by microbiome-derived metabolites, resulting in exacerbating vaso-occlusive crisis (VOC) in sickle cell disease. In KRICT, Dr. Lee is working on diagnosis of infectious disease in human by using mouse mimic models. He has been developing microfluidics platform in order to diagnose the disease sensitively but fast by using pathogen proteins or immune cell-derived systems. It would be simple and easy to diagnose and handle disease. Dr. Lee has received his Ph.D. degree in immunology at Sungkyunkwan University

 

  1. Yoo Jin Joo,Ph.D (TiumBio)

Yoo Jin Joo is a Team leader of the Discovery department in R&D center at TiumBio Inc. The ultimate goal of his research is to understand the regulation mechanism of eukaryotic gene expression. While working at Harvard Medical School as Research Associate, he had been developed the biochemical reconstitution system coupled with quantitative mass spectrometry to study the mechanistic connection between transcription and epigenetic regulation. Now, heโ€™s trying to translate what he found in academia to the therapeutic development in the industry field. Yoo Jin received his B.S. in genetic engineering, M.S and Ph.D. degrees in Biochemistry from Korea University.

๋ฏธ๊ตญ๊ธฐ์—…์ทจ์—… ํŒจ๋„ ์ •๋ณด
  1. Jinrang Kim, Ph.D. (Regeneron)

Jinrang (Jin) Kim is a staff scientist in the Department of Muscle & Metabolism at Regeneron Pharmaceuticals. He joined Regeneron in 2014 as a postdoctoral fellow and transitioned into a scientist in 2017. He received his Ph.D. in Biological Sciences from Columbia University in 2012 and studied membrane protein biophysics for his graduate work. His current research aims to understand the pathophysiology of type 1 diabetes (T1D) to develop new therapeutic molecules to prevent pancreatic beta cell death in patients with T1D.

 

  1. Patrick Hong, Ph.D. (Cellectis)

Dr. Patrick Hong is a principal scientist at Cellectis where he is currently leading a team of researchers to develop a stem cell therapy using TALEN-based gene editing technology. Prior to his role at Cellectis, Dr. Hong was a staff scientist at Regeneron Pharmaceautical and post-doctoral researcher at Icahn school of medicine at Mount Sinai. During his post-doc, Dr. Hong studied a negative-strand RNA virus to be used for a gene delivery system. Dr. Hong received his B.S. and Ph.D. degrees in Microbiology and Molecular Genetics from UCLA.

 

  1. Jeewon Garcia-So, Ph.D. (Pendulum Therapeutics)

Jeewon Garcia-So, Ph.D. is a senior scientist at Pendulum Therapeutics, a company targeting patient care through human microbiome. Jeewon received her Ph.D. in Nutritional and Metabolic Biology at Columbia University in 2019 with her research focusing on protective role of omega-3 fatty acids against infection-related preterm birth. Her role at Pendulum focuses on building scientific credibility of the companyโ€™s first product, Pendulum Glucose Control, via conducting preclinical and clinical testing.

์ œ 13ํšŒ NYKB ํ•™์ˆ ๋Œ€ํšŒ ์ผ์ • ๋ฐ ํ”„๋กœ๊ทธ๋žจ ์•ˆ๋‚ด

4์›” 16์ผ (20:00 – 23:00 EST)

20:00-20:05 Welcoming Address

๋ฐฑ์ •์€ ๋ฐ•์‚ฌ (President of NYKB, MSKCC)

20:05-20:10 Opening Remarks

๋ฐ•์ค€์„ ๋ฐ•์‚ฌ (President of NEBS, Harvard University)

20:10-20:40 Keynote Speaker I (์ขŒ์žฅ: ๊น€์Šน์ˆ˜ ๋ฐ•์‚ฌ)

๊น€์„  ๊ต์ˆ˜ (Seoul National University)

Title: Modeling cells using multi-omics data with AI technologies

20:40-20:55 NYKB Fellowship I (์ขŒ์žฅ: ์ž„์œค์˜ ๋ฐ•์‚ฌ)

์ตœ์ธ์„ญ ๋ฐ•์‚ฌ (Icahn School of Medicine at Mount Sinai)

Title: Microglial Autophagy Controls Homeostasis of ฮฑ-synuclein and Protects Dopaminergic Neurons

20:55-21:55 ์Šฌ๊ธฐ๋กœ์šด ๊ธฐ์—…์ƒํ™œ (Mingle with K-industries) (์ง„ํ–‰์ž: ๋ฐ•๊ด‘์ˆ˜ ๋ฐ•์‚ฌ)

– LG Chem (ํ™์„ฑ์› ์ƒ๋ฌด/์‹ ์•ฝ์—ฐ๊ตฌ์„ผํ„ฐ์žฅ, LG์ƒ๋ช…๊ณผํ•™)

– Samyang (๋ฐฐ๋ช…ํ˜ธ ์—ฐ๊ตฌ๊ธฐํš ํŒ€์žฅ, ์‚ผ์–‘ํ™€๋”ฉ์Šค ์˜์•ฝ๋ฐ”์ด์˜ค์—ฐ๊ตฌ์†Œ)

– Daewoong (๋ฐ•์ค€์„ ์—ฐ๊ตฌ๋ณธ๋ถ€ ์‹ ์•ฝ์„ผํ„ฐ์žฅ, ๋Œ€์›…์ œ์•ฝ)

– Yuhan (์œคํƒœ์ง„ ์ƒ๋ฌด/์ „๋žต์‹ค์žฅ, ์œ ํ•œ์–‘ํ–‰)

– Seegene (๊น€ํ˜ธ์ค€ ์—ฐ๊ตฌ์ธํ”„๋ผ์šด์˜ํŒ€์žฅ, ์”จ์  )

21:55-22:55 Networking Session (Homecoming OB & YB mixer) (์•ˆ๋‚ด์ž: ๊น€์Šน์ˆ˜ ๋ฐ•์‚ฌ)

– Breakroom#1 (Albert Einstein, ์ง„ํ–‰์ž: ๊น€์Šน์ˆ˜๋ฐ•์‚ฌ)

– Breakroom#2 (Columbia Univ., ์ง„ํ–‰์ž: ์˜ค์˜ํƒ ๋ฐ•์‚ฌ)

– Breakroom#3 (Cold Spring Harbor Laboratory, ์ง„ํ–‰์ž: ์ด์žฌํ˜• ๋ฐ•์‚ฌ)

– Breakroom#4 (Icahn School of Medicine at Mount Sinai, ์ง„ํ–‰์ž: ์ž„์œค์˜ ๋ฐ•์‚ฌ)

– Breakroom#5 (Memorial Sloan Kettering Cancer Center, ์ง„ํ–‰์ž: ๋ฐฑ์ •์€ ๋ฐ•์‚ฌ)

– Breakroom#6 (New York Univ., ์ง„ํ–‰์ž: ์œคํƒœ์ง„ ๋ฐ•์‚ฌ)

– Breakroom#7 (Rockefeller Univ., ์ง„ํ–‰์ž: ์ด๋™ํ›ˆ ๋ฐ•์‚ฌ)

– Breakroom#8 (Rutgers Univ., ์ง„ํ–‰์ž: ์ •์œ ์˜ ๋ฐ•์‚ฌ)

– Breakroom#9 (Stony Brook Univ., ์ง„ํ–‰์ž: ์–‘์ข…์› ๋ฐ•์‚ฌ๊ณผ์ •)

– Breakroom#10 (Weill Cornell Medicine, ์ง„ํ–‰์ž: ๊ฐ•์„คํฌ ๋ฐ•์‚ฌ)

22:55 – 23:00 Closing Remarks

๊น€์Šน์ˆ˜ ๋ฐ•์‚ฌ (Vice President of NYKB)

 

4์›” 17์ผ (09:00 – 12:00 EST)

09:00-09:05 Opening Remarks

๊ฐ•์ •๋ฏผ ๋ฐ•์‚ฌ (President of KOLIS, Stanford University)

09:05-09:35 Keynote Speaker II (์ขŒ์žฅ: ์œคํƒœ์ง„ ๋ฐ•์‚ฌ)

์˜ค์„ฑํ™˜ ๊ต์ˆ˜ (Harvard University)

Title: Mining Metabolites from Microbiota

09:35-09:50 NYKB Fellowship II (์ขŒ์žฅ: ์ด๋™ํ›ˆ ๋ฐ•์‚ฌ)ย 

์˜ค์˜ํƒ ๋ฐ•์‚ฌ (Columbia University)

Title: Functional validation of a novel classification of glioblastoma

09:50-10:50 Career Development Mentoring Session (์•ˆ๋‚ด์ž: ๊ฐ•์„คํฌ ๋ฐ•์‚ฌ)

ย  Breakroom#1 ์ฐฝ์—… (์ง„ํ–‰์ž: ์ž„์œค์˜ ๋ฐ•์‚ฌ)

ย  ํŒจ๋„: ์ •์ง€์—ฐ ๋ฐ•์‚ฌ (Yumanity Therapeutics), ์ด๊ทผ์šฐ ๋ฐ•์‚ฌ(Genedit), ์ž„์„ฑ์› ๋ฐ•์‚ฌ (ImpriMed)

ย  Breakroom#2 ๊ตญ๋‚ด๊ต์ˆ˜์ž„์šฉ (์ง„ํ–‰์ž: ์˜ค์˜ํƒ ๋ฐ•์‚ฌ)

ย  ํŒจ๋„: ์ž„์ •ํ˜„ ๊ต์ˆ˜ (์ „๋ถ๋Œ€), ๊น€๊ฒฝ์ง„ ๊ต์ˆ˜(์ธํ•˜๋Œ€), ์ตœ์žฌํ›ˆ ๊ต์ˆ˜ (ํ•œ์–‘๋Œ€)

ย  Breakroom#3 ๋ฏธ๊ตญ๊ต์ˆ˜ ์ž„์šฉ (์ง„ํ–‰์ž: ์–‘์ข…์›/๋…ธ๋‹ค์€)

ย  ํŒจ๋„: ์–‘ํฌ์› ๊ต์ˆ˜ (Columbia), ์ •์ƒ๋ฌด ๊ต์ˆ˜ (Johns hopkins), ๊น€ํ™˜๊ทผ ๊ต์ˆ˜ (Stony)

ย  Breakroom#4 ๊ตญ๋‚ด๊ธฐ์—…์ทจ์—… (์ง„ํ–‰์ž: ๊ฐ•์„คํฌ ๋ฐ•์‚ฌ)

ย  ํŒจ๋„: ๊น€์šฐ์ˆ™ ๋ฐ•์‚ฌ (LG์ƒ๋ช…๊ณผํ•™), ์ด์„ฑ๊ท  ๋ฐ•์‚ฌ (ํ•œ๊ตญํ™”ํ•™์—ฐ๊ตฌ์†Œ), ์ฃผ์œ ์ง„ ๋ฐ•์‚ฌ (TiumBio)

ย  Breakroom#5 ๋ฏธ๊ตญ๊ธฐ์—…์ทจ์—… (์ง„ํ–‰์ž: ์ •์œ ์˜ ๋ฐ•์‚ฌ)

ย  ํŒจ๋„: ๊น€์ง„๋ž‘ ๋ฐ•์‚ฌ (Regeneron), ํŒจํŠธ๋ฆญํ™ ๋ฐ•์‚ฌ (Cellectis), ์†Œ์ง€์› ๋ฐ•์‚ฌ (Pendulum Therapeutics)

10:50-11:05 NYKB Fellowship III (์ขŒ์žฅ: ์ •์œ ์˜ ๋ฐ•์‚ฌ)

์ž„์€์ฃผ ๋ฐ•์‚ฌ๋‹˜ (New York Univ.)

Title: APP-ฮฒCTF Regulates v-ATPase-mediated Lysosomal Acidification

11:05-11:50 Poster Session and Networking (์•ˆ๋‚ด์ž: ์ด์žฌํ˜• ๋ฐ•์‚ฌ)

Breakroom#1 ๊ถŒ๋ถ€๊ธฐ ๋ฐ•์‚ฌ (MSKCC)

Breakroom#2 ๊น€์Šน์ˆ˜ ๋ฐ•์‚ฌ (Columbia University)

Breakroom#3 ๊น€ํƒœ์™„ ๋ฐ•์‚ฌ (MSKCC)

Breakroom#4 ๊น€ํ˜œ์ง„ ๋ฐ•์‚ฌ (Columbia University)

Breakroom#5 ๋ฐ•๊ธฐํƒœ ๋ฐ•์‚ฌ๊ณผ์ • (Columbia University)

Breakroom#6 ๋ฐ•์ง€์œค ๋ฐ•์‚ฌ๊ณผ์ • (Stony Brook University)

Breakroom#7 ๋ฐ•ํ˜•์ฃผ ๋ฐ•์‚ฌ (MSKCC)

Breakroom#8 ๋ณต์„œ์—ฐ ๋ฐ•์‚ฌ (Weill Cornell Medicine)

Breakroom#9 ์„ฑ๊ธฐ์‚ฌ ๋ฐ•์‚ฌ (Icahn School of Medicine at Mount Sinai)

Breakroom#10 ์†ก์„ธ๋ผ ๋ฐ•์‚ฌ (Columbia University)

Breakroom#11 ์˜ค์˜ํƒ ๋ฐ•์‚ฌ (Columbia University)

Breakroom#12 ์œคํƒœ์ง„ ๋ฐ•์‚ฌ (New York University)

Breakroom#13 ์œค์ฐฝํ™˜ ๋ฐ•์‚ฌ (MSKCC)

Breakroom#14 ์ด์—ฌ์ง„ ๋ฐ•์‚ฌ (Columbia University)

Breakroom#15 ์ž„์„ฑ์ˆœ ๋ฐ•์‚ฌ (Columbia University)

Breakroom#16 ์ž„์€์ • ๋ฐ•์‚ฌ (MSKCC)

Breakroom#17 ์ž„์€์ฃผ ๋ฐ•์‚ฌ (New York University)

Breakroom#18 ์ •ํƒœ๋ฌธ ๋ฐ•์‚ฌ (Cold Spring Harbor Laboratory)

Breakroom#19 ์กฐ์ฐฝํ›ˆ ๋ฐ•์‚ฌ (Albert Einstein College of Medicine)

Breakroom#20 ํ˜ธ์ค€ ๋ฐ•์‚ฌ (MSKCC)

Breakroom#21 ํ™ฉ์„ฑ๋ฏผ ๋ฐ•์‚ฌ (Weill Cornell Medicine)

11:50-12:00 Breakย 
12:00-12:05 Sponsor Talk

๋ฐ•์ˆœ๋งŒ ๋ฏธ์ฃผ์ง€์‚ฌ์žฅย (Korea Health Industry Development Institute)

12:05-12:15 Fellowship/ Poster Award Ceremony (์ง„ํ–‰์ž: ๋ฐฑ์ •์€ ๋ฐ•์‚ฌ)

๊ฒฝํ’ˆ์ถ”์ฒจย  (์ง„ํ–‰์ž: ์–‘์ข…์› & ๋…ธ๋‹ค์€)

12:15-12:20 Closing Remarks

๋ฐ•๊ด‘์ˆ˜ ๋ฐ•์‚ฌ (Vice President of NYKB)